InMed Pharmaceuticals Inc (NASDAQ: INM) shares are trading lower after the company released safety and efficacy results from its Phase 2 clinical trial (755-201-EB) for
Greenbrook TMS (NASDAQ:GBNH) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.43) by 4.65 percent. This is a 14.58 percent increase over losses of $(0.48) per share from the